# RNN 2nd Gen Model Merck & Company, Inc. Pharmaceutical preparations

Stock predictor AI models:
Subscribe >> Deal exit on
Dec. 14, 2020
Deal entry on
Dec. 14, 2020
11.02%Expected margin
70.37% successful of 27 deals
$ 88.05 Last close price
at 29-oct-2021

MRK

Model's trade recommendations No return for period yet

3.91% Annual return

$236.57B Market Cap

β 0.37  

MRK

Model (following trade recommendations)

MRK

Underlying stock

S&P 500

Index
Return for period
5.96%
1.78%
52wk return 30.31%
17.07%
16.82%
52wk Range
70.30—88.05
2000.54—2399.63
Sortino ratio 0.79
Sharpe ratio 0.53
Norm. RMSE 9.63%
Downside risk 4.77%
Volatility 0.00%
  • 2.76 (2.95%) Div (Yield)
  • BUY Analysts consensus recommendation

Merck & Co. boasts more than six blockbuster drugs in its portfolio with PD-L1 inhibitor, Keytruda, approved for several types of cancer. Keytruda has played an instrumental role in driving Merck's steady revenue growth in the past few years. Well-known products in Merck's portfolio include Keytruda, Simponi , Januvia and Janumet, Bridion, Isentress, ProQuad, Gardasil, Pneumovax 23, RotaTeq and Belsomra. Merck made its biggest acquisition of Schering-Plough and sold off its Consumer Care business to Bayer. Other key acquisitions include Idenix Pharmaceuticals, Cubist Pharmaceuticals, Rigontec, ArQule and Acceleron Pharma. IMerck spun off products from its Women's Health unit, legacy drugs and biosimilar products into a new publicly traded company called Organon & Co.

Industry sector: Medical

Sector classification: Pharmaceutical preparations

Deep Learning based analysis and prediction model for Merck & Company, Inc. (MRK) stock is a 2nd Generation Non-linear Autoregressive (NAR) model based on the LSTM/GRU Recurrent Neural Network architecture.

Model is in the production pipeline since Sept. 10, 2014.

Market data for MRK model training are being downloaded from the Quandl premium datasets on a daily basis.
Risks related to the novel coronavirus disease 2019 (COVID-19) caused by the virus named “SARS-CoV-2” are accounted for in this model in the form of the historical data coincided with outbreaks and other global events in the past used to train ML prediction model for MRK.

Model is being retrained on a regular basis.

Float 2521M
P/E 13.36
Shares Outstanding 2529M
% Held by Insiders 0.29%
% Held by Institutions 72.88%
EPS (last reported FY) $6.02
EPS (last reported Q) $2.14
EPS, estimated (last reported Q) $1.81
Total revenues $49 B
Net income $13 B